596 results on '"Kim, H.R."'
Search Results
2. Eco-friend air electrode for flexible quasi-solid-state electrolyte zinc-air battery based on spherical glucose biochar derived from biorefinery process
3. Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study
4. Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck
5. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
6. 117TiP BGB-HNSCC-201 (NCT05909904): Phase II, open-label, multi-arm, global study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in patients (Pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
7. 122P Casdozokitug (casdozo, SRF388), a first-in-class IL-27 targeting antibody, as monotherapy (monotx) or in combination with pembrolizumab (pembro) in treatment-refractory non-small cell lung cancer (NSCLC)
8. EP12.01-47 Lazertinib in Pretreated Epidermal Growth Factor Receptor T790M-Mutated Advanced Non-small Cell Lung Cancer: A Real-World Multicenter Study
9. P1.28-11 Recurrence Dynamics for Pathological N2 Non-small Cell Lung Cancer depending on the IASLC Residual Tumor Descriptor
10. MA13.11 Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial
11. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
12. Effectiveness of oral counselling for smoke cessation in Graves orbitopathy patients
13. Efectividad del consejo médico para dejar de fumar en pacientes con orbitopatía de Graves
14. WCN23-1000 Initial Emergency Room 6-hour Urine Volume is an Important Factor for the Survival of Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
15. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma
16. OD1-3 Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea
17. 148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)
18. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
19. Evaluation of microwave-dried black soldier fly (Hermetia illucens) larvae meal as a dietary protein source in broiler chicken diets
20. OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
21. EP08.02-012 Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea
22. P1.11-01 Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
23. EP08.01-073 AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
24. 992P Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC)
25. EP05.03-005 Clinical Impact of Histologic Type in Patients with Surgically Resected Stage II and III Non-small Cell Lung Cancer
26. EP05.03-004 Risk Prediction of Multiple-station N2 Metastasis in Patients with Clinical Single-station N2 Non-small Cell Lung Cancer
27. P20-10 A new murine liver fibrosis model induced by polyhexamethylene guanidine-phosphate
28. 1017P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)
29. O177 Impact of heat stress on physiological responses and nitrogen utilisation in growing pigs
30. Zebrafish as a model for von Hippel Lindau and hypoxia-inducible factor signaling
31. 29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results
32. Metastasising fibroblasts show an HDAC6-dependent increase in migration speed and loss of directionality linked to major changes in the vimentin interactome
33. Blood urea nitrogen to creatinine ratio as a potential biomarker for prediction of hypoactive delirium in critical illness patients
34. Development and assessment of system analysis code, TASS/SMR for integral reactor, SMART
35. POS-608 DRY WEIGHT ADJUSTMENTS FOR HEMODIALYSIS PATIENTS USING MACHINE LEARNING
36. POS-634 BODY FAT MASS PLAYS A IMPORTANT ROLE IN OVER- OR UNDERESTIMATION OF BIOIMPEDANCE SPECTROSCOPY-BASEDDRY WEIGHT FOR THE PATIENTS WITH HEMODIALYSIS
37. P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy
38. P50.09 Characteristics and Clinical Outcomes of HER2 Mutated Non-small Cell Lung Cancer Patients Detected by NGS in Routine Clinical Practice
39. P59.01 Clinical Characteristics of Patients With MET Amplification-Positive NSCLC After EGFR-TKI Therapy
40. 895P Disproportional enrichment of FoxP3+CD4+ regulatory T-cells shapes a suppressive tumor microenvironment and provokes anti–PD-1 resistance in head and neck squamous cell carcinoma
41. 973P A phase II study of PDR001 among patients with recurrent and/or metastatic esophageal squamous cell carcinoma: An interim analysis of KM-12
42. 1195P Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L
43. 1197P First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN
44. 1254P Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC
45. 860MO Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC)
46. Design and development of 500 m long HTS cable system in the KEPCO power grid, Korea
47. 2096P Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
48. 1305P Importance of the resected lung tumor specimen in patients with locally advanced and metastatic non-small cell lung cancer undergoing prior targeted therapy
49. 1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
50. 1338P Cerebrospinal fluid pharmacokinetic study of lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG21-01 LAZARUS trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.